Immunovia
0.577
SEK
-2.04 %
IMMNOV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
-2.04%
-5.72%
-8.41%
-33.68%
-22.05%
-34.45%
-57.69%
-98.79%
-99.1%
-95.79%
immunovia.com
Immunovia is a biotechnology company. The company's research and development is focused on molecular diagnostics, where the business focuses on driving the development and change of current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests to be able to identify different types of pancreatic cancer at an early stage. The company was founded in 2007 and is headquartered in Lund.
Revenue
1.58M
EBIT %
-18,763.29 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
IMMNOV
Daily low / high price
0.566 / 0.595
SEK
Market cap
97.92M SEK
Turnover
192.38K SEK
Volume
335K
Financial calendar
Interim report
2024-11-27
Annual report
2025-02-25
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Försäkringsbolaget Avanza Pension | 7.8 % | 7.8 % |
| Carl Borrebaeck | 3.8 % | 3.8 % |
| Vincent Saldell | 2.2 % | 2.2 % |
| Sara Andersson Ek | 1.9 % | 1.9 % |
| Per Mats Ohlin | 1.9 % | 1.9 % |
| Christer Wingren | 1.7 % | 1.7 % |
| Handelsbanken Livförsäkring AB | 1.5 % | 1.5 % |
| Sten Johnsson | 1.0 % | 1.0 % |
| Jens Henrik Jensen | 0.9 % | 0.9 % |
| Nordnet Pensionsförsäkring AB | 0.9 % | 0.9 % |
ShowingAll content types
Immunovia AB: Immunovia presenterar data från modellutvecklingsstudien vid årsmötet för The Collaborative Group of the Americas-Inherited Gastrointestinal Cancers
Immunovia AB: Inbjudan till Immunovias presentation av Q3
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools